Free shipping on all orders over $ 500

LY364947

Cat. No. M2016

All AbMole products are for research use only, cannot be used for human consumption.

LY364947 Structure
Synonym:

HTS 466284

Size Price Availability Quantity
5mg USD 60 In stock
10mg USD 80 In stock
50mg USD 295 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

LY-364947 is a selective, ATP-competitive inhibitor of Transforming Growth Factor-β Type I receptor kinase. LY364947 inhibits TGF-β-dependent luciferase production in mink lung cells (p3TP lux) and growth in mouse fibroblasts (NIH 3T3) (IC50 values are 47 and 89 nM respectively). LY364947 is much less potent at related kinases, with IC50 of 400 nM for TGF-β RII and IC50 of 1400 nM for mixed lineage kinase-7 (MLK-7), a kinase in the MAP kinase signal pathway and closely related to TGF-β RII. LY364947 (3 μM) induces expression of Prox1 and LYVE-1 in almost all HDLECs after 24 hours. LY364947 (25 mg/kg) increases p-Akt and decreases nuclear Foxo3a in leukaemia-initiating cells in CML-affected mice.

Product Citations
Customer Product Validations & Biological Datas
Source Cancer Res (2012). Figure 1. LY364947
Method clonogenic assay
Cell Lines radiosensitizes glioma cells
Concentrations 400 nM
Incubation Time 24 h
Results Regardless of TGFβ-mediated growth modulation, addition of the TGFβ inhibitor LY364947 significantly increased the radiosensitivity of all three cell lines as measured in clonogenic assay
Chemical Information
Molecular Weight 272.31
Formula C17H12N4
CAS Number 396129-53-6
Solubility (25°C) DMSO 10 mg/mL (ultrasonic and warming)
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
References

[1] Bouquet F, et al. Clin Cancer Res. TGFβ1 inhibition increases the radiosensitivity of breast cancer cells in vitro and promotes tumor control by radiation in vivo.

[2] Vogt J, et al. Cell Signal. The specificities of small molecule inhibitors of the TGFß and BMP pathways.

[3] Shiou SR, et al. Cancer Res. Smad4 regulates claudin-1 expression in a transforming growth factor-beta-independent manner in colon cancer cells.

Related TGF-β Receptor Products
LY2157299

LY2157299 (Galunisertib) is a novel clinically relevant TBRI (ALK5 kinase) inhibitor with IC50 of 56 nM.

GW788388

GW788388 is a potent selective inhibitor of TGF-beta type I receptor and ALK5 with IC50 values of 0.093 and 0.018 μM.

LY2109761

LY2109761 is a novel TGF-β receptor type I and type II dual inhibitor, with Ki values of 38 nM and 300 nM, respectively.

SB-525334

SB-525334 is a potent activin receptor-like kinase (ALK5)/ type I TGFβ-receptor kinase inhibitor with IC50 of 14.3 nM.

SB-505124

Sb-505124 is a selective inhibitor of TGF-βI receptor (ALK4, ALK5, ALK7) with IC50 values of 129 nM and 47 nM for ALK4 and ALK5, respectively. Sb-505124 also inhibits ALK7, but not ALK1, 2, 3 and 6.

  Catalog
Abmole Inhibitor Catalog




Keywords: LY364947, HTS 466284 supplier, TGF-β Receptor, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.